

---

# Guidance for Industry

## Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act

### *DRAFT GUIDANCE*

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Nancy Boocker 301-796-3601.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**Procedural**

**January 2009**

---

# Guidance for Industry

## Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act

*Additional copies are available from:  
Office of Training and Communication  
Division of Drug Information, HFD-240  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Ave.,  
Bldg. 51, Room 2201  
Silver Spring, MD 20993-0002  
(Tel) 301-796-3400  
<http://www.fda.gov/cder/guidance/index.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**Procedural**

**January 2009**

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION</b> .....	<b>1</b>
<b>II.</b>	<b>BACKGROUND</b> .....	<b>2</b>
<b>A.</b>	<b>Scope of Section 505(q)</b> .....	<b>2</b>
<b>B.</b>	<b>Determination of Delay</b> .....	<b>2</b>
<b>C.</b>	<b>Certification and Verification</b> .....	<b>3</b>
<b>D.</b>	<b>Final Agency Action</b> .....	<b>3</b>
<b>E.</b>	<b>Judicial Review</b> .....	<b>3</b>
<b>F.</b>	<b>Exceptions and Reporting</b> .....	<b>4</b>
<b>III.</b>	<b>DISCUSSION</b> .....	<b>4</b>
<b>A.</b>	<b>How Does FDA Determine if Section 505(q) Applies to a Particular Petition?</b> .....	<b>4</b>
1.	<i>Petition Submitted on or after September 27, 2007</i> .....	<b>5</b>
2.	<i>Petition Submitted in Writing and Pursuant to § 10.30 or 10.35</i> .....	<b>5</b>
3.	<i>ANDA or 505(b)(2) Application Is Pending at the Time the Petition Is Submitted</i> .....	<b>6</b>
4.	<i>Petition Requests an Action That Could Delay Approval of a Pending ANDA or 505(b)(2) Application</i> .....	<b>7</b>
5.	<i>Petition Does Not Fall Within Any of the Exceptions Described in Section 505(q)(4)</i> .....	<b>7</b>
<b>B.</b>	<b>How Does FDA Determine if a Petition Would Delay Approval of an ANDA or 505(b)(2) Application?</b> .....	<b>7</b>
<b>C.</b>	<b>How Does FDA Apply the Certification Requirements in Section 505(q)(1)(H)?</b> .....	<b>9</b>
<b>D.</b>	<b>How Does FDA Apply the Verification Requirements in Section 505(q)(1)(I)?</b> .....	<b>10</b>
<b>E.</b>	<b>What Is the Relationship Between the Review of Petitions Under Section 505(q) and the Review of ANDAs and 505(b)(2) Applications for Which the Agency Has Not Yet Made a Final Decision on Approvability?</b> .....	<b>11</b>

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**Guidance for Industry<sup>1</sup>**

**Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act**

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

**I. INTRODUCTION**

This guidance provides information regarding FDA's (or the Agency's) current thinking on interpreting section 914 of Title IX of the Food and Drug Administration Amendments Act (FDAAA).<sup>2</sup> Section 914 of FDAAA adds new section 505(q) to the Federal Food, Drug, and Cosmetic Act (the Act)<sup>3</sup> and governs certain citizen petitions and petitions for stay of Agency action that request that FDA take any form of action related to a pending application submitted under section 505(b)(2) or 505(j) of the Act.<sup>4</sup>

This guidance describes FDA's interpretation of section 505(q) regarding how the Agency determines if (1) the provisions of section 505(q) addressing the treatment of citizen petitions and petitions for stay of Agency action (collectively, petitions) apply to a particular petition and (2) a petition would delay approval of a pending abbreviated new drug application (ANDA) or 505(b)(2) application. This guidance also describes how FDA interprets the provisions of section 505(q) requiring that (1) a petition include a certification and (2) supplemental information or comments to a petition include a verification<sup>5</sup> and addresses the relationship between the review of petitions and pending ANDAs and 505(b)(2) applications for which the Agency has not yet made a decision on approvability.

<sup>1</sup> This guidance has been prepared by the Office of Regulatory Policy in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.

<sup>2</sup> Public Law 110-85 (as amended by Public Law 110-316).

<sup>3</sup> 21 U.S.C. 355(q). For brevity, in this guidance, references to section 505(q) of the Act are cited as section 505(q).

<sup>4</sup> 21 U.S.C. 355(b)(2) and (j). In this guidance, an application submitted under section 505(b)(2) of the Act is referred to as a 505(b)(2) application and an application submitted under section 505(j) of the Act is referred to as an abbreviated new drug application (ANDA).

<sup>5</sup> Section 505(q)(1)(E) provides that FDA may issue guidance to describe the factors that will be used to determine whether a petition is submitted with the primary purpose of delaying the approval of an application. This guidance does not address the factors under section 505(q)(1)(E). Any guidance issued pursuant to section 505(q)(1)(E) will be issued separately from this guidance. FDA also is considering issuing regulations through notice and comment rulemaking to further implement section 505(q).

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

35  
36 FDA’s guidance documents, including this guidance, do not establish legally enforceable  
37 responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should  
38 be viewed only as recommendations, unless specific regulatory or statutory requirements are  
39 cited. The use of the word *should* in Agency guidances means that something is suggested or  
40 recommended, but not required.

41

42

### **II. BACKGROUND**

43

44  
45 FDAAA was enacted on September 27, 2007. Section 914 of Title IX of FDAAA took effect on  
46 the date of enactment and amended section 505 of the Act by adding a new subsection (q).  
47 Section 505(q) applies to certain petitions that request that FDA take any form of action related  
48 to a pending ANDA or 505(b)(2) application and governs the manner in which these petitions are  
49 treated. The provisions of section 505(q) are described in greater detail below.

50

#### **A. Scope of Section 505(q)**

51

52  
53 Section 505(q)(1)(A), together with section 505(q)(5), describes the general scope of section  
54 505(q). Section 505(q)(1)(A) provides:

55

56 The Secretary shall not delay approval of a pending application submitted under  
57 subsection (b)(2) or (j) because of any request to take any form of action relating to the  
58 application, either before or during consideration of the request, unless—

59

- 60 (i) the request is in writing and is a petition submitted to the Secretary pursuant  
61 to section 10.30 or 10.35 of title 21, Code of Federal Regulations (or any  
62 successor regulations); and  
63 (ii) the Secretary determines, upon reviewing the petition, that a delay is  
64 necessary to protect the public health.

65

66 In section 505(q)(5), the term *application* is defined as an application submitted under section  
67 505(b)(2) or 505(j) of the Act and the term *petition* is defined as a request described in  
68 505(q)(1)(A)(i).

69

#### **B. Determination of Delay**

70

71  
72 If FDA determines that a delay of approval of an ANDA or 505(b)(2) application is necessary to  
73 protect the public health, FDA is required to provide to the applicant not later than 30 days after  
74 making the determination:

75

- 76 1. notification that the determination has been made,  
77 2. if applicable, any clarification or additional data that the applicant should submit to  
78 the petition docket to allow FDA to review the petition promptly, and  
79 3. a brief summary of the specific substantive issues raised in the petition which form  
80 the basis of the determination.<sup>6</sup>

---

<sup>6</sup> Section 505(q)(1)(B).

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

81  
82 At FDA’s discretion, the information is to be conveyed by either a document or a meeting with  
83 the applicant.<sup>7</sup> The information conveyed as part of the notification is to be considered part of  
84 the application and subject to the disclosure requirements applicable to information in such  
85 application.<sup>8</sup>

### **C. Certification and Verification**

86  
87  
88 Under section 505(q)(1)(H), FDA may not consider a petition for review unless the petition is in  
89 writing and signed and contains a certification that is specified in that section. In addition, FDA  
90 may not accept for review any supplemental information or comments on a petition unless the  
91 submission is in writing and signed and contains a specific verification.<sup>9</sup>

### **D. Final Agency Action**

92  
93  
94  
95 Section 505(q)(1)(F) governs the timeframe for final Agency action on a petition. Under this  
96 provision, FDA shall take final Agency action on a petition not later than 180 days after the date  
97 on which the petition is submitted. The 180-day period is not to be extended for any reason,  
98 including any determination made under section 505(q)(1)(A) regarding delay of approval of an  
99 application, the submission of comments or supplemental information, or the consent of the  
100 petitioner.

101  
102 FDA may deny a petition at any point if the Agency determines that a petition or a supplement to  
103 the petition was submitted with the primary purpose of delaying the approval of an application  
104 and the petition does not on its face raise valid scientific or regulatory issues.<sup>10</sup> FDA may issue  
105 guidance to describe the factors that will be used to determine whether a petition is submitted  
106 with the primary purpose of delaying the approval of an application.<sup>11</sup>

### **E. Judicial Review**

107  
108 Section 505(q)(2) governs judicial review of final Agency action. Under section 505(q)(2)(A),  
109 FDA shall be considered to have taken final Agency action on a petition if FDA makes a final  
110 decision within the meaning of 21 CFR 10.45(d) during the 180-day period or the 180-day period  
111 expires without FDA having made a final decision. Under section 505(q)(2)(B), if a civil action  
112 is filed against the Secretary with respect to any issues raised in the petition before final Agency  
113 action, a court shall dismiss the action without prejudice for failure to exhaust administrative  
114 remedies. Section 505(q)(2)(C) describes the information to be included in the administrative  
115 record.  
116  
117  
118  
119

---

<sup>7</sup> Section 505(q)(1)(C).

<sup>8</sup> Section 505(q)(1)(D).

<sup>9</sup> Section 505(q)(1)(I).

<sup>10</sup> Section 505(q)(1)(E).

<sup>11</sup> Section 505(q)(1)(E). As noted in footnote 5, any guidance issued pursuant to section 505(q)(1)(E) will be issued separately from this guidance.

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

### 120 **F. Exceptions and Reporting**

121  
122 Section 505(q)(4) exempts certain categories of petitions from the provisions of section 505(q)  
123 — in particular, petitions relating to 180-day generic drug exclusivity and petitions from a  
124 505(b)(2) or ANDA applicant regarding FDA actions with respect to that application. Section  
125 505(q)(3) and section 914(b) of FDAAA also provide for certain reporting requirements from  
126 FDA to Congress.

127

128

### 129 **III. DISCUSSION**

130

131 As described in section II of this guidance, the provisions of section 505(q) addressing the  
132 treatment of petitions apply only to certain petitions. These provisions include, for example, the  
133 requirements that approval of an ANDA or 505(b)(2) application not be delayed by a petition  
134 absent an Agency determination that a delay is necessary to protect the public health, the  
135 provisions requiring final Agency action on the petition within 180 days of submission, and the  
136 provisions requiring a certification or a verification.

137

138 We describe below how we determine:

- 139
- if the provisions of section 505(q) apply to a particular petition
  - if a petition would delay approval of a pending ANDA or 505(b)(2) application

141

142 We also describe how we interpret:

- 143
- section 505(q)(1)(H) requiring that a petition include a certification
  - section 505(q)(1)(I) requiring that supplemental information or comments on a  
145 petition include a verification

146

147 We also describe the relationship between the review of petitions under section 505(q) and the  
148 review of ANDAs and 505(b)(2) applications for which the Agency has not yet made a final  
149 decision on approvability.

150

### 151 **A. How Does FDA Determine if Section 505(q) Applies to a Particular Petition?**

152

153 We interpret section 505(q) to apply to a petition only if the petition meets all of the following  
154 criteria:

155

- 156
- The petition is submitted to FDA on or after September 27, 2007.
  - The petition is submitted in writing and pursuant to 21 CFR 10.30 or 10.35.
  - An ANDA or 505(b)(2) application is pending at the time the petition is submitted to  
159 FDA.
  - The petitioner requests an action that could delay approval of a pending ANDA or  
161 505(b)(2) application.
  - The petition does not fall within any of the exceptions described in section 505(q)(4).

163

164 We discuss each criterion in greater detail below.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207

### *1. Petition Submitted on or after September 27, 2007*

Because section 914 of FDAAA became effective on September 27, 2007, we believe that the provisions of section 505(q) only apply to petitions that are submitted on or after September 27, 2007. We do not believe that section 505(q) applies to any petitions that were submitted before September 27, 2007, because section 505(q) does not state that it applies retroactively to petitions submitted before the effective date. In addition, such an interpretation might impose a 180-day deadline for responding to a petition after the 180 days have already expired.

Even if section 505(q) were interpreted to retroactively apply to pre-September 27, 2007, petitions, FDA would not be able to review any petition submitted before September 27, 2007, because those petitions would not contain the required certification and, as explained in section III.C of this guidance, the statute does not permit a petitioner to cure the deficiency by supplementing a pre-September 27, 2007, petition to add the certification to the petition.

### *2. Petition Submitted in Writing and Pursuant to § 10.30 or 10.35*

Under section 505(q) of the Act, a petition must be submitted in writing and pursuant to § 10.30 or 10.35. Section 10.30 of our regulations describes FDA’s general requirements for submitting a citizen petition, and § 10.35 describes our requirements for submitting a request for administrative stay of action. If these criteria are not met, we will not consider section 505(q) to apply to the petition.

We note that communications with the Agency regarding any issues intended to delay the approval of an ANDA or 505(b)(2) application (regardless of whether the communications are considered to be petitions subject to section 505(q)) are appropriately submitted through the petition process pursuant to § 10.30 or 10.35 rather than as correspondence to the NDA, ANDA, or 505(b)(2) application or another process. Similarly, any communications regarding a citizen petition should be filed as comments in the appropriate docket, not to the NDA, ANDA, or 505(b)(2) application.

We also remind persons that they may not cross-reference or rely upon information that is not included in the petition. Under §§ 10.30(b) and 10.35(b), petitions must be submitted in accordance with 21 CFR 10.20. Section 10.20(c) requires that “[i]nformation referred to or relied upon in a submission is to be included in full and may not be incorporated by reference, unless previously submitted in the same proceeding.” In addition, the certification required for petitions subject to section 505(q) (described in section III.C of this guidance) and the certification required for citizen petitions under § 10.30(b) require the petitioner to certify that “this petition includes all information and views upon which the petition relies.” A petition therefore is required to include all information referred to or relied upon by the petitioner. In addition, the petition should contain all information, both favorable and unfavorable, regarding the petitioner’s claims.



## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

### 3. *ANDA or 505(b)(2) Application Is Pending at the Time the Petition Is Submitted*

Section 505(q)(1)(A) describes the scope of section 505(q) (see section II of this guidance). Section 505(q)(1)(A) specifically references pending applications and contemplates the possibility that approval could be delayed by issues raised in a petition. Therefore, we interpret section 505(q) to apply only to petitions for which, at the time the petition is submitted, at least one ANDA or 505(b)(2) application related to the subject matter of the petition is pending.<sup>12</sup> If there is no related ANDA or 505(b)(2) application pending at the time that the petition is submitted, then we will not consider the provisions of section 505(q) to apply to the petition. We believe this interpretation is appropriate because if no related ANDA or 505(b)(2) application is pending at the time that a petition is submitted, the references in section 505(q)(1)(A) to a pending application and delay of approval by a petition would be inapplicable.

We also believe our interpretation is appropriate to ensure the fair and orderly implementation of section 505(q). Because application of the provisions of section 505(q) flows from a determination that a petition is within the scope of section 505(q), the evaluation of whether a related ANDA or 505(b)(2) application is pending needs to be made at the time that the petition is submitted. If we were to take a “rolling” evaluation approach, the status of the petition could change at any time from one that is not subject to section 505(q) to one that is subject to section 505(q) should a related ANDA or 505(b)(2) application be submitted before we have taken final Agency action on the petition. Such a change in the status of the petition would disrupt the orderly application of the provisions of section 505(q) and also could prejudice petitioners and commenters.

For example, as described in sections III.C and D of this guidance, to be reviewed by FDA, any petition subject to section 505(q) must include a certification and any comments to a petition subject to section 505(q) must include a verification. If, after submission, a petition’s status were converted from not being subject to section 505(q) to being subject to section 505(q), a petitioner who did not include a certification in the petition and/or commenter who did not include a verification in the comments would be prejudiced because the petition or the comments would not be eligible for review by FDA.

For these reasons, we interpret section 505(q) to apply only to petitions for which, at the time the petition is submitted, at least one ANDA or 505(b)(2) application related to the subject matter of the petition is pending. We recognize that petitioners may not be aware of the existence of a pending application. Therefore, we encourage all petitioners challenging the approvability of a possible ANDA or 505(b)(2) application to include the certification required in section 505(q)(1)(H).

---

<sup>12</sup> Although the existence of a pending application generally is not made public by FDA, a potential petitioner may be aware of the existence of a pending ANDA or 505(b)(2) application, because of (1) a paragraph IV patent notification, from the applicant to the new drug application (NDA) holder and the patent owner, stating that the application has been submitted and explaining the factual and legal bases for the applicant’s opinion that the patent is invalid or not infringed (see section 505(b)(2)(B) and (j)(2)(B) of the Act), (2) a public announcement by the applicant disclosing the submission of the application, or (3) the tentative approval of an ANDA or 505(b)(2) application made public by FDA or the applicant. In addition, FDA’s Web site identifies drug products for which the Agency has received an ANDA with a paragraph IV certification.

## Contains Nonbinding Recommendations

Draft — Not for Implementation

247 4. *Petition Requests an Action That Could Delay Approval of a Pending ANDA or*  
248 *505(b)(2) Application*  
249

250 As noted, section 505(q)(1)(A) contemplates the possibility that approval of a pending ANDA or  
251 505(b)(2) application could be delayed by issues raised in the petition.<sup>13</sup> Therefore, we interpret  
252 section 505(q) to apply only to petitions that request an action that could delay approval of a  
253 pending ANDA or 505(b)(2) application. If the action requested by the petition could not delay  
254 approval of the application under any reasonable theory, we will not consider the provisions of  
255 section 505(q) to apply to the petition.  
256

257 5. *Petition Does Not Fall Within Any of the Exceptions Described in Section*  
258 *505(q)(4)*  
259

260 Section 505(q)(4) provides that section 505(q) will not apply to any petitions that:  
261

- 262 1. relate solely to the timing of approval of an application pursuant to the 180-day  
263 exclusivity provision at section 505(j)(5)(B)(iv) of the Act, or
- 264 2. are from the sponsor of the ANDA or 505(b)(2) application and seek only to have FDA  
265 take or refrain from taking any action with respect to that application.  
266

267 If either of these exceptions applies, we will not consider the provisions of section 505(q) to  
268 apply to the petition.  
269

270 **B. How Does FDA Determine if a Petition Would Delay Approval of an ANDA or**  
271 **505(b)(2) Application?**  
272

273 Under section 505(q)(1)(A), FDA shall not delay approval of an ANDA or 505(b)(2) application  
274 because of a petition unless the Agency determines that a delay is necessary to protect the public  
275 health. To implement this provision, first we determine if the provisions of section 505(q) apply  
276 to the petition based on the criteria described in section III.A of this guidance. If the provisions  
277 apply, we then determine if the petition may be summarily denied as described in section  
278 505(q)(1)(E) (which allows denial of a petition that was submitted with the primary purpose of  
279 delaying approval of an application and does not on its face raise valid scientific or regulatory  
280 issues).  
281

282 If we do not find that the petition may be summarily denied, we will determine if the petition  
283 would be the cause of a delay in an approval of an ANDA or 505(b)(2) application by using a *but*  
284 *for* test. In other words, would the ANDA or 505(b)(2) application be ready for approval but for  
285 the issues raised by the petition?  
286

---

<sup>13</sup> We note that there are means other than submission of a petition by which interested persons can express their views on issues related to bioequivalence. FDA has been posting draft product-specific bioequivalence recommendations on its Web site at <http://www.fda.gov/cder/guidance/bioequivalence/default.htm> and announcing in a *Federal Register* notice the availability of these recommendations and the opportunity for the public to consider and comment on the recommendations. We encourage interested persons to submit any comments related to bioequivalence issues in response to a *Federal Register* notice announcing the recommendations.

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

- 287
- 288
- 289
- 290
- 291
- 292
- If, regardless of the petition, the ANDA or 505(b)(2) application would not be ready for approval, then section 505(q)(1)(A) would not be implicated.<sup>14</sup>
  - If the ANDA or 505(b)(2) application would be ready for approval but for the petition, then we would next determine if a delay of approval is necessary to protect the public health.

293

294 We determine if a delay of approval is necessary to protect the public health based on our

295 preliminary evaluation of the issues raised in the petition. The Agency considers the following:

296

297 If the application were approved before the Agency completed the substantive

298 review of the issues in the petition and, after further review, the Agency

299 concluded that the petitioner’s arguments against approval were meritorious,

300 could the presence on the market of drug products that did not meet the

301 requirements for approval negatively affect the public health?

302

303 If, after undertaking this analysis, we conclude that the public health could be negatively

304 affected, the Agency will conclude that a delay “is necessary to protect the public health” and

305 will delay approval of the pending application. Issues that could implicate the public health

306 include, for example, (1) whether a proposed generic drug product is bioequivalent to the

307 reference listed drug or (2) whether an indication can be safely omitted from the labeling because

308 that indication is protected by a patent.

309

310 If we determine that a delay is necessary, we will notify the applicant as required by section

311 505(q)(1)(B) and (C) of the Act. Under these provisions, we are required to provide the

312 following information to the applicant not later than 30 days after making the determination:

- 313
- 314
- 315
- 316
- 317
- Notification that the determination has been made
  - If applicable, any clarification or additional data that the applicant should submit to the petition docket to allow FDA to review the petition promptly
  - A brief summary of the specific substantive issues raised in the petition which form the basis of the determination
- 318

319 At our discretion, we will convey this information to the applicant by either a letter or a meeting

320 with the applicant.<sup>15</sup> As provided in section 505(q)(1)(D), we will consider the information

321 conveyed in the notification to be part of the application and subject to the disclosure

322 requirements applicable to information in such application. We do not intend to notify the

323 petitioner if a determination has been made that a delay in approval of an application is necessary

324 to protect the public health because the provisions of section 505(q) do not require such a

325 notification to the petitioner.

326

327 If we determine that a delay of approval is not necessary to protect the public health, we will

328 proceed with approving the application.

---

<sup>14</sup> We note, however, that a petition would still be subject to section 505(q) as long as a relevant application is pending at the time the petition is submitted.

<sup>15</sup> See section 505(q)(1)(C).

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372

### **C. How Does FDA Apply the Certification Requirements in Section 505(q)(1)(H)?**

Section 505(q)(1)(H) of the Act provides that FDA shall not consider a petition for review unless the petition is in writing and signed and contains the following certification:

I certify that, to my best knowledge and belief: (a) this petition includes all information and views upon which the petition relies; (b) this petition includes representative data and/or information known to the petitioner which are unfavorable to the petition; and (c) I have taken reasonable steps to ensure that any representative data and/or information which are unfavorable to the petition were disclosed to me. I further certify that the information upon which I have based the action requested herein first became known to the party on whose behalf this petition is submitted on or about the following date: \_\_\_\_\_ [in the blank space, provide the date on which such information first became known to such party]. If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations: \_\_\_\_\_ [in the blank space, provide the names of such persons or organizations]. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this petition.

This certification includes statements in addition to those described under § 10.30(b) for the certification in citizen petitions.

We apply section 505(q)(1)(H) to require that all petitions that fall within the scope of section 505(q) be in writing and signed, and contain the complete 505(q) certification to be considered for review by FDA. If, based on the criteria described in section II.A of this guidance, section 505(q) applies to the petition, but the petition is not in writing or signed, or does not contain the complete certification, we will not review the petition.

We also apply section 505(q)(1)(H) to require that the certification be included in the original petition. Section 505(q)(1)(H) refers to the “petition” as the subject document that must contain the certification. Because sections 505(q)(1)(E) and 505(q)(1)(I) distinguish between petitions and supplements to petitions,<sup>16</sup> the reference to a petition in section 505(q)(1)(H) refers only to the original petition and not to a supplement. Therefore, if a petition is missing the complete certification, we will not permit a petitioner to cure the deficiency by submitting a supplement to add the certification to the petition.

If a petitioner has submitted a petition that is missing the required certification but is otherwise within the scope of section 505(q) and the petitioner would like FDA to review the petition, the petitioner should (1) submit a letter withdrawing the deficient petition pursuant to § 10.30(g) and (2) submit a new petition that contains the certification. In this case, the provisions of section 505(q) governing the treatment of petitions will apply only to the new petition that includes the required certification because we cannot review the deficient petition under section 505(q)(1)(H).

---

<sup>16</sup> Section 505(q)(1)(E) states that if FDA determines that a petition or a supplement to the petition was submitted with the primary purpose of delaying approval of an application, the Agency may deny the petition at any point. Section 505(q)(1)(I) requires that supplemental information include a verification as described in section III.D of this guidance.

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

373 In particular, we consider the 180-day timeframe for FDA to respond to the petition to begin  
374 from the date of submission of the new, complete petition and not the original, deficient petition.  
375

376 Because FDA will not review a petition that is subject to section 505(q) but is missing the  
377 required certification, we strongly encourage all petitioners raising issues that could delay the  
378 approval of a possible ANDA or 505(b)(2) application to include the certification in their  
379 petitions to ensure FDA consideration. Although we may contact a petitioner to notify him or  
380 her of a missing or deficient certification, we note that it is the responsibility of the petitioner to  
381 ensure that its petition complies with the applicable requirements of section 505(q), as well as all  
382 other applicable statutory and regulatory requirements.  
383

### **D. How Does FDA Apply the Verification Requirements in Section 505(q)(1)(I)?**

384  
385  
386 Section 505(q)(1)(I) provides that FDA shall not accept for review any supplemental information  
387 or comments on a petition unless the supplemental information or comments are in writing,  
388 signed, and contain the following verification:  
389

390 I certify that, to my best knowledge and belief: (a) I have not intentionally delayed  
391 submission of this document or its contents; and (b) the information upon which I have  
392 based the action requested herein first became known to me on or about \_\_\_\_\_ [in  
393 the blank space, provide the date on which such information first became known to such  
394 party]. If I received or expect to receive payments, including cash and other forms of  
395 consideration, to file this information or its contents, I received or expect to receive those  
396 payments from the following persons or organizations: \_\_\_\_\_ [in the blank space,  
397 provide the names of such persons or organizations]. I verify under penalty of perjury  
398 that the foregoing is true and correct as of the date of the submission of this petition.  
399

400 Section 505(q)(1)(I) applies to any supplemental information or comments that are submitted to  
401 a petition that is subject to section 505(q). If any such supplemental information or comments do  
402 not include the required verification, FDA will not review the submission.  
403

404 If a petitioner or commenter has submitted supplemental information or comments without the  
405 required verification or with an incomplete verification and the petitioner or commenter would  
406 like FDA to review the submission, the petitioner or commenter should resubmit the  
407 supplemental information or comments with the required verification to FDA.  
408

409 For petitions that are subject to section 505(q), because FDA will not review any supplemental  
410 information or comments that are missing the required verification, we strongly encourage all  
411 petitioners or commenters to include the verification in their supplemental information or  
412 comments to a petition that includes the 505(q) certification to ensure FDA consideration. We  
413 will not notify petitioners and commenters of a missing or deficient verification. In some  
414 instances, FDA receives numerous supplements and comments in a docket, and it would be  
415 administratively burdensome to monitor all the dockets for 505(q) petitions and notify  
416 commenters about the statutory requirement. It is the responsibility of petitioners and  
417 commenters to ensure that their supplemental information or comments comply with the  
418 applicable requirements of section 505(q), as well as all other applicable statutory and regulatory  
419 requirements.  
420

## *Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

421  
422 **E. What Is the Relationship Between the Review of Petitions Under Section 505(q) and**  
423 **the Review of ANDAs and 505(b)(2) Applications for Which the Agency Has Not**  
424 **Yet Made a Final Decision on Approvability?**  
425

426 A petition may request that FDA take an action related to a specific aspect of a pending ANDA  
427 or 505(b)(2) application for which the Agency will not have made a final decision regarding  
428 approvability by the date that the petition response is due. As described in section II.D., section  
429 505(q)(1)(F) requires FDA to take final Agency action on a petition within 180 days of  
430 submission. The review of applications that may be affected by the petition is governed by a  
431 separate review process, which will not necessarily be completed by the date the petition  
432 response is due. If a petition requests that the Agency take an action related to a specific aspect  
433 of a pending application, we will consider the review status of the affected application(s) in  
434 determining whether it would be appropriate for the Agency to respond to the request to take the  
435 action requested in the petition within the 180-day timeframe.

436  
437 The provisions in section 505 of the Act and FDA's regulations at 21 CFR part 314 establish  
438 certain procedures by which the Agency reviews an NDA or ANDA and notifies an applicant if  
439 it determines that an application is approved (§ 314.105) or may not be approved (section 505(c)  
440 and 505(j); §§ 314.125 and 314.127), or identifies the deficiencies in the application and the  
441 steps an applicant may take to respond to the deficiencies (§ 314.110). In addition, the statute  
442 and regulations describe a specific process through which an applicant whose application the  
443 Agency has found not to meet the requirements for approval may challenge the Agency's  
444 determination (section 505(c)(1)(B) and (d), 505(j)(5)(E); § 314.200). Under this process, the  
445 Agency must give the applicant notice of an opportunity for a hearing on whether the application  
446 is approvable, with a specific timeframe and process should the applicant request such a hearing.  
447 These procedures ensure that applicants have an adequate opportunity to challenge a finding by  
448 the Agency that a product does not meet the requirements for approval.

449  
450 By contrast, responses to citizen petitions, including petitions subject to section 505(q),  
451 constitute final Agency action and are subject to immediate review by the courts. They therefore  
452 carry with them none of the procedural rights for the affected applicants that attach to a decision  
453 to deny approval of an application. If we were to respond substantively a petitioner's request  
454 regarding the approvability of a certain aspect of a pending application before we have taken a  
455 final action on the approvability of the application as a whole, such response could interfere with  
456 the statutory and regulatory scheme governing the review of applications and related procedural  
457 rights of applicants.<sup>17</sup> There is no evidence that in enacting section 505(q), Congress intended to  
458 limit applicants' procedural rights by requiring that the Agency make decisions that constitute  
459 final Agency action on the approvability of specific aspects of a pending application (e.g., the  
460 acceptability of a proposed trade name, specific claims proposed in a drug product's labeling) on  
461 a piecemeal basis outside of the process established under the Act and regulations.<sup>18</sup>

---

<sup>17</sup> We also note that under applicable statutory and regulatory provisions, we are generally prohibited from disclosing information regarding applications that have not yet been approved. Depending upon the nature and specificity of a petition, these limitations on disclosure also may circumscribe the Agency's ability to respond substantively to issues raised in a petition that affect a pending application.

<sup>18</sup> In the past, we have responded to requests related to general standards for approval (e.g., bioequivalence criteria for generic drug products or the appropriateness of omitting certain protected information from proposed drug

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472

Therefore, we do not interpret section 505(q) to require a substantive final Agency decision within 180 days on the approvability of a specific aspect of a pending application when a final decision on the approvability of the application as a whole has not yet been made and when to render such a decision could deprive an applicant of procedural rights established by statute and regulations. In such a situation, we would expect to deny a petition without comment on the substantive approval issue.

---

product labeling) that may pertain to one or more pending drug applications, without commenting on the approvability of any particular aspect of a specific pending application. We distinguish our approach of responding to petitions that involve general policies or standards for approval of a drug application from our approach described above, which applies to petitions that involve narrow issues of approvability of a specific aspect or aspects of a pending application. We will continue to evaluate each citizen petition on a case-by-case basis with respect to the appropriateness of responding to the petitioner's requests vis-à-vis any pending applications.